 |
|
Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity With Systemic Oxidative Stress and Cardiovascular Risk
Tamali Bhattacharyya, MD, MS;
Stephen J. Nicholls, MBBS, PhD;
Eric J. Topol, MD;
Renliang Zhang, MD, PhD;
Xia Yang, PhD;
David Schmitt, BA;
Xiaoming Fu, MS;
Mingyuan Shao, MS;
Danielle M. Brennan, MS;
Stephen G. Ellis, MD;
Marie-Luise Brennan, PhD;
Hooman Allayee, PhD;
Aldons J. Lusis, PhD;
Stanley L. Hazen, MD, PhD
JAMA. 2008;299(11):1265-1276.
Context Paraoxonase 1 (PON1) is reported to have antioxidant and cardioprotective properties. The relationship between PON1 genotypes and functional activity with systemic measures of oxidative stress and cardiovascular disease (CVD) risk in humans has not been systematically investigated.
Objective To investigate the relationship of genetic and biochemical determinants of PON1 activity with systemic measures of oxidative stress and CVD risk in humans.
Design, Setting, and Participants The association between systemic PON1 activity measures and a functional polymorphism (Q192R) resulting in high PON1 activity with prevalent CVD and future major adverse cardiac events (myocardial infarction, stroke, or death) was evaluated in 1399 sequential consenting patients undergoing diagnostic coronary angiography between September 2002 and November 2003 at the Cleveland Clinic. Patients were followed up until December 2006. Systemic levels of multiple structurally defined fatty acid oxidation products were also measured by mass spectrometry in 150 age-, sex-, and race-matched patients and compared with regard to PON1 genotype and activity.
Main Outcome Measures Relationship between a functional PON1 polymorphism and PON1 activity with global indices of systemic oxidative stress and risk of CVD.
Results The PON1 genotype demonstrated significant dose-dependent associations (QQ192 > QR192 > RR192) with decreased levels of serum PON1 activity and with increased levels of systemic indices of oxidative stress. Compared with participants with either the PON1 RR192 or QR192 genotype, participants with the QQ192 genotype demonstrated an increased risk of all-cause mortality (43/681 deaths [6.75%] in RR192 and QR192 and 62/584 deaths [11.1%] in QQ192; adjusted hazard ratio, 2.05; 95% confidence interval [CI], 1.32-3.18) and of major adverse cardiac events (88/681 events [13.6%] in RR192 and QR192 and 102/584 events [18.0%] in QQ192; adjusted hazard ratio, 1.48; 95% CI, 1.09-2.03; P = .01). The incidence of major adverse cardiac events was significantly lower in participants in the highest PON1 activity quartile (23/315 [7.3%]) and 235/324 [7.7%] for paraoxonase and arylesterase, respectively) compared with those in the lowest activity quartile (78/311 [25.1%] and 75/319 [23.5%]; P < .001 for paraoxonase and arylesterase, respectively). The adjusted hazard ratios for major adverse cardiac events between the highest and lowest PON1 activity quartiles were, for paraoxonase, 3.4 (95% CI, 2.1-5.5; P < .001) and for arylesterase, 2.9 (95% CI, 1.8-4.7; P < .001) and remained independent in multivariate analysis.
Conclusion This study provides direct evidence for a mechanistic link between genetic determinants and activity of PON1 with systemic oxidative stress and prospective cardiovascular risk, indicating a potential mechanism for the atheroprotective function of PON1.
Author Affiliations: Department of Cell Biology (Drs Bhattacharyya, Nicholls, Zhang, M.-L. Brennan, and Hazen and Messrs Schmitt and Fu), Center for Cardiovascular Diagnostics and Prevention (Drs Bhattacharyya, Nicholls, Zhang, M.-L. Brennan, and Hazen and Messrs Schmitt and Fu), and Department of Cardiovascular Medicine (Drs Nicholls, Ellis, and Hazen, Mr Shao, and Ms D. M. Brennan), Cleveland Clinic, Cleveland, Ohio; Scripps Research Institute and Scripps Clinic, La Jolla, California (Dr Topol); Departments of Medicine (Drs Yang and Lusis), Human Genetics (Dr Lusis), and Microbiology and Immunology (Dr Lusis), University of California, and Department of Preventive Medicine, University of Southern California (Dr Allayee), Los Angeles.
RELATED LETTER
Homocysteine Levels, Paraoxonase 1 (PON1) Activity, and Cardiovascular Risk
Eddie Vos
JAMA. 2008;300(2):168-169.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
SHISHEHBOR and HAZEN
Cleveland Clinic Journal of Medicine 2009;76:37-44.
ABSTRACT
| FULL TEXT
Genetic Polymorphisms in the Paraoxonase 1 Gene and Risk of Ovarian Epithelial Carcinoma
Lurie et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:2070-2077.
ABSTRACT
| FULL TEXT
Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation
Shimano et al.
Europace 2008;10:961-966.
ABSTRACT
| FULL TEXT
Is homocysteine a mediator of atrial dysfunction or just another marker of endothelial dysfunction?
Van Wagoner
Europace 2008;10:899-900.
FULL TEXT
Homocysteine Levels, Paraoxonase 1 (PON1) Activity, and Cardiovascular Risk
Vos
JAMA 2008;300:168-169.
FULL TEXT
Genetics and Genomics for Clinicians
Fontanarosa et al.
JAMA 2008;299:1364-1365.
FULL TEXT
Paraoxonase 1, Oxidative Stress, and Atherosclerosis
Journal Watch Cardiology 2008;2008:4-4.
FULL TEXT
|
